ENRIGHT PATRICK G

Director Enright buys 1,075,000 shares at $17.00 for $18.3M; cluster pattern with 4 other insiders buying in past 14 days.

Director Patrick G. Enright executed 2 separate purchases totaling 1,075,000 shares at $17.00 on 2026-02-05 for $18,275,000.00, increasing his holdings from 978,474 shares to 2,053,474 shares—a +109.9% increase. This filing occurs at a time of significant cluster activity, with 4 other insiders also buying within the past 14 days, suggesting coordinated interest at the post-IPO entry point. The transaction occurred 2 trading days after listing, at a price $20.16 below the current market price of $37.16. However, the presence of a derivative-conversion element noted in this filing means Enright's full position extends beyond the Table I shares shown, and the reported holdings do not represent his complete stake; investors should review Form 4 Table II when available for the full derivative picture before drawing conclusions about net exposure changes.

VERA Director Enright purchases 5,882 shares at $42.50; extends prior accumulation pattern with 4 consecutive buys at ticker.

Patrick Enright, a Director at Vera Therapeutics, purchased 5,882 shares for $249,985.00 at $42.50 on 2025-12-11, establishing an initial position in the stock. This transaction marks the fifth consecutive buy from this insider at VERA: he has made four prior purchases at this ticker on 2025-06-23 and 2025-06-24, all of which generated positive 90-day returns (ranging from +16.8% to +22.6%). The current purchase occurs at $42.50 versus today's price of $49.21, placing the transaction in the lower half of the 52-week range ($18.86–$49.80). Against his cross-ticker track record of 8 prior buys (average 90d return -6.0%), his same-ticker history at VERA stands out notably: 4 of 4 prior buys were well-timed at the 90-day mark, contrasting with a 66.67% 90d win rate across all holdings. However, the company reported a net loss of $-80,293,000.00 in its most recent full fiscal year, presenting a fundamental backdrop of ongoing unprofitability that bears on the context of this accumulation.

Director Patrick G. Enright buys 117,255 shares for $2.3M at ZBIO; joins 5 other insiders buying in past 14 days as stock rallies +97.8% in 90 days.

Director Patrick G. Enright executed 2 separate open-market purchases totaling 117,255 shares for $2,250,026.50 on 2025-10-09, at a blended average price of $19.19. The timing is notable: the stock has risen +97.8% over the past 90 days and currently trades at $25.85, up +27.8% in just 30 days—well above the blended purchase price. Enright's prior buy at ZBIO on 2024-09-16 proved poorly timed, falling -47.5% over 90 days, though his cross-ticker track record shows a 66.67% win rate on 90-day hold periods. Most significantly, this buy is part of a cluster: 5 other insiders also purchased ZBIO shares within the past 14 days, suggesting coordinated confidence or response to material information at an unprofitable biotech (FY net income: $-52,223,000) with zero latest-quarter revenue.

Director ENRIGHT PATRICK G bought 250,000 shares for $5,277,311.42 across 4 transactions on 2025-06-23 and 2025-06-24.

Patrick G. Enright, a director at Vera Therapeutics, executed 4 separate purchases totaling 250,000 shares for $5,277,311.42 on June 23–24, 2025, raising his holdings from 3,346,593 to 3,596,593 shares—a 7.5% increase in his position at an average price of $21.11. This is notable in light of Vera's recent financial distress: the company reported a full-year net income of $-51,694,000.00 and is currently trading at $23.31, down 53.2% from its 52-week high of $49.75 despite a 30-day rally of +18.7%. Enright's cross-ticker trading history shows 2 prior open-market buys with a 0.00% 90-day win rate and an average 90-day return of -57.4%, indicating that his past purchase decisions have not preceded favorable near-term price performance. The size and timing of this $5.3M accumulation in a loss-making biotech company under a director warrant scrutiny, particularly given the asymmetry between his purchase activity and his demonstrated difficulty timing entries across his portfolio.

Director Patrick Enright purchased 400,000 shares of BIOA at $18.00 ($7.2M) in post-IPO window; 4 insiders buying within 14 days

Director Patrick Enright purchased 400,000 shares at $18.00 on 2024-09-27, increasing his holdings from 1,310,589 shares to 1,710,589 shares—a +30.5% increase in his equity stake. The transaction occurs just 2 trading days after BioAge Labs' recent listing and at a price $3.00 below the current $21.00 market price. Notably, a cluster pattern shows 4 other insiders also bought within the past 14 days, suggesting coordinated accumulation during the early public trading window. This filing contains a derivative-conversion transaction; the full extent of Enright's position includes securities in Table II that are not yet populated in the database, so reported Table I holdings represent only a portion of his beneficial interest.

Director Enright purchases 440,000 shares of ZBIO for $7.5M; cluster of 5 other insider buys in 14 days

Patrick G. Enright, a director at Zenas BioPharma, purchased 440,000 shares at $17.00 on 2024-09-16, just 2 trading days after the company's recent listing, increasing his holdings from 334,530 to 774,530 shares (+131.5%). The current price stands at $17.97, marginally above his transaction price. This transaction is part of a broader pattern: 5 other insiders also bought within the past 14 days, forming a cluster buy signal. While Enright's purchase represents a substantial $7,480,000 commitment, the company's very recent listing status means longer-term valuation context is not yet available. The convergence of multiple insider purchases post-listing merits investor attention, though the derivative-conversion nature of this filing means his full position includes securities not yet visible in the filing's Table I holdings.